Paragon Biosciences has launched a new company, Qlarity Imaging, to specialize in artificial intelligence (AI) for improved medical outcomes.
The company plans to have Qlarity Imaging further develop QuantX, a computer-aided breast cancer diagnosis platform that has received clearance from the U.S. Food and Drug Administration (FDA). QuantX initially was developed at the University of Chicago with the collaboration of Quantitative Insights, a startup conceived with the support of the university's Polsky Center for Entrepreneurship and Innovation.
Qlarity Imaging also is looking to expand diagnostic applications of its AI technology to additional image modalities and medical conditions to enhance patient care and reduce costs for hospitals and payors.
Qlarity Imaging is the third company launched by Paragon Biosciences in less than a year and the seventh launched since 2017.
